No causal effects of plasma homocysteine levels on the risk of coronary heart disease or acute myocardial infarction: A Mendelian randomization study

Abstract

Background

Although many observational studies have shown an association between plasma homocysteine levels and cardiovascular diseases, controversy remains. In this study, we estimated the role of increased plasma homocysteine levels on the etiology of coronary heart disease and acute myocardial infarction.

Methods

A two-sample Mendelian randomization study on disease was conducted, i.e. “coronary heart disease” (n = 184,305) and “acute myocardial infarction” (n = 181,875). Nine single nucleotide polymorphisms, which were genome-wide significantly associated with plasma homocysteine levels in 57,644 subjects from the Coronary ARtery DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease (C4D) Genetics (CARDIoGRAMplusC4D) consortium genome-wide association study and were known to be associated at p < 5×10^–8, were used as an instrumental variable.

Results

None of the nine single nucleotide polymorphisms were associated with coronary heart disease or acute myocardial infarction (p > 0.05 for all). Mendelian randomization analysis revealed no causal effects of plasma homocysteine levels, either on coronary heart disease (inverse variance weighted; odds ratio = 1.015, 95% confidence interval = 0.923–1.106, p = 0.752) or on acute myocardial infarction (inverse variance weighted; odds ratio = 1.037, 95% confidence interval = 0.932–1.142, p = 0.499). The results were consistent in sensitivity analyses using the weighted median and Mendelian randomization-Egger methods, and no directional pleiotropy (p = 0.213 for coronary heart disease and p = 0.343 for acute myocardial infarction) was observed. Sensitivity analyses confirmed that plasma homocysteine levels were not significantly associated with coronary heart disease or acute myocardial infarction.

Conclusions

The findings from this Mendelian randomization study indicate no causal relationship between plasma homocysteine levels and coronary heart disease or acute myocardial infarction. Conflicting findings from observational studies might have resulted from residual confounding or reverse causation.

Keywords

Two-sample mendelian randomization genome-wide association study plasma homocysteine levels coronary heart disease acute myocardial infarction causation

Get full access to this article

View all access options for this article.

References

Chiu

Heydari

Batulan

, et al. Coronary artery disease in post-menopausal women: Are there appropriate means of assessment?. Clin Sci (Lond) 2018; 132: 1937–1952.

Madhavan

Gersh

Alexander

, et al. Coronary artery disease in patients ≥80 years of age. J Am Coll Cardiol 2018; 71: 2015–2040.

Abram

Arruda-Olson

Scott

, et al. Frequency, predictors, and implications of abnormal blood pressure responses during dobutamine stress echocardiography. Circ Cardiovasc Imaging 2017; 10: e005444.

Yamada

Matsui

Takeuchi

, et al. Association of genetic variants with coronary artery disease and ischemic stroke in a longitudinal population-based genetic epidemiological study. Biomed Rep 2015; 3: 413–419.

Jensen

Bertoia

Cahill

, et al. Novel metabolic biomarkers of cardiovascular disease. Nat Rev Endocrinol 2014; 10: 659–672.

Jakubowski

. Homocysteine modification in protein structure/function and human disease. Physiol Rev 2019; 99: 555–604.

Yang

Fan

Zhi

, et al. Prevalence of hyperhomocysteinemia in China: A systematic review and meta-analysis. Nutrients 2014; 7: 74–90.

Emdin

Khera

Kathiresan

. Mendelian randomization. JAMA 2017; 318: 1925–1926.

Bennett

Holmes

. Mendelian randomisation in cardiovascular research: An introduction for clinicians. Heart 2017; 103: 1400–1407.

10.

Hartwig FP, Davies NM, Hemani G, et al. Two-sample Mendelian randomization: Avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol 2016; 45: 1717–1726.

11.

Bowden

Del Greco

Minelli

, et al. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med 2017; 36: 1783–1802.

12.

Nikpay

Goel

Won

, et al. A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 2015; 47: 1121–1130.

13.

van Meurs

Pare

Schwartz

, et al. Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. Am J Clin Nutr 2013; 98: 668–676.

14.

Pare

Chasman

Parker

, et al. Novel associations of CPS1, MUT, NOX4, and DPEP1 with plasma homocysteine in a healthy population: A genome-wide evaluation of 13 974 participants in the Women's Genome Health Study. Circ Cardiovasc Genet 2009; 2: 142–150.

15.

Purcell

Neale

Todd-Brown

, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575.

16.

Geng

Smith

, et al. Childhood BMI and adult type 2 diabetes, coronary artery diseases, chronic kidney disease, and cardiometabolic traits: A Mendelian randomization analysis. Diabetes Care 2018; 41: 1089–1096.

17.

Johnson

Handsaker

Pulit

, et al. SNAP: A Web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008; 24: 2938–2939.

18.

Bowden

Davey Smith

Burgess

. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int J Epidemiol 2015; 44: 512–525.

19.

Davey Smith

Hemani

. Mendelian randomization: Genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 2014; 23: R89–R98.

20.

Palmer

Lawlor

Harbord

, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 2012; 21: 223–242.

21.

Burgess

Butterworth

Thompson

. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013; 37: 658–665.

22.

Liu

Zhang

, et al. Causal effects of genetically predicted cardiovascular risk factors on chronic kidney disease: A two-sample mendelian randomization study. Front Genet 2019; 10: 415.

23.

Hemani

Zheng

Elsworth

, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 2018; 7: e34408.

24.

Mokry

Ross

Timpson

, et al. Obesity and multiple sclerosis: A Mendelian randomization study. PLoS Med 2016; 13: e1002053.

25.

Curro

Gugliandolo

Gangemi

, et al. Toxic effects of mildly elevated homocysteine concentrations in neuronal-like cells. Neurochem Res 2014; 39: 1485–1495.

26.

Wald

Law

Morris

. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 2002; 325: 1202.

27.

Olsen

Vinknes

Svingen

, et al. The risk association of plasma total homocysteine with acute myocardial infarction is modified by serum vitamin A. Eur J Prev Cardiol 2018; 25: 1612–1620.

28.

Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002; 288: 2015–2022. .

29.

Liu

Chen

Dong

, et al. Association of prehypertension and hyperhomocysteinemia with subclinical atherosclerosis in asymptomatic Chinese: A cross-sectional study. BMJ Open 2018; 8: e019829.

30.

Zhao

Chen

Liu

, et al. Role of hyperhomocysteinemia and hyperuricemia in pathogenesis of atherosclerosis. J Stroke Cerebrovasc Dis 2017; 26: 2695–2699.

31.

Cook

Taylor

Orloff

, et al. Homocysteine and arterial disease. Experimental mechanisms. Vascul Pharmacol 2002; 38: 293–300.

32.

Marti-Carvajal

Sola

Lathyris

, et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2017; 8: CD006612.

33.

Shoamanesh A Preis

Beiser

, et al. Circulating biomarkers and incident ischemic stroke in the Framingham Offspring Study. Neurology 2016; 87: 1206–1211. .

34.

Veeranna

Zalawadiya

Niraj

, et al. Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol 2011; 58: 1025–1033.

35.

Goff

DC Lloyd-Jones

Bennett

, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S49–S73.

36.

Perk

De Backer

Gohlke

, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635–1701.

37.

Badsha

. Learning causal biological networks with the principle of Mendelian randomization. Front Genet 2019; 10: 460.

38.

Nitsch

Molokhia

Smeeth

, et al. Limits to causal inference based on Mendelian randomization: A comparison with randomized controlled trials. Am J Epidemiol 2006; 163: 397–403.

39.

Chen

Yang

Chang

, et al. Homocysteine is a bystander for ST-segment elevation myocardial infarction: A case-control study. BMC Cardiovasc Disord 2018; 18: 33.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.10 MB